Compare Charles River Laboratories Intl. Inc (CRL) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while YieldMax MSTR Option Income Strategy ETF trades at $15.75 (market cap $1.06B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 13.4× YieldMax MSTR Option Income Strategy ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and YieldMax MSTR Option Income Strategy ETF for 30 Days on average.
| CRL | MSTY | |
|---|---|---|
Market Cap | $14.23B | $1.06B |
Volume | 1,176,885 | 2,402,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $310.77 | $67.85 |
52-Week Low | $149.93 | $11.55 |
Typical Hold Time | 33 Days | 30 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
MSTY, the YieldMax MSTR Option Income Strategy ETF, trades at $15.83, down 5.61% with a bearish technical signal. The fund generates weekly distributions through options strategies on MicroStrategy stock, with recent payouts ranging from $0.16 to $0.34. Despite high distribution rates exceeding 100% annualized, the fund has experienced significant NAV erosion, declining approximately 34% over six months according to 24/7 Wall Street analysis from July 2026.
The outlook remains challenging as MSTY's strategy sacrifices capital appreciation for income generation. While the high distribution rate provides income, the structural erosion of NAV presents substantial risk. Investors face the dual challenge of receiving taxable distributions while experiencing principal decline, making this suitable only for those prioritizing current income over capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
